(RTTNews) – Novavax, Inc. (NVAX) has submitted a Phase 2b clinical trial in South Africa to compare the efficacy of NVX-CoV2373, the company’s COVID-19 candidate vaccine. In Phase 1 of the Phase 1/2 clinical trial in Australia, NVX-CoV2373 was well tolerated and showed numerically impressive physically powerful antibody responses than those observed in human convalescent serums.
NVX-CoV2373 is a prefusion protein manufactured with the company’s nanoparticle generation and includes the Matrix-M adjuvant. The Coalition for Innovations in Epidemic Preparedness (CEPI) budgets for the manufacture of doses of NVX-CoV2373 for the Phase 2b clinical trial.